---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093930"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:09:30.472362+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%

## Summary
- GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.
- Cash, equivalents and investments $186.2M; sufficient to fund operations into Q1 2026.
- R&D expenses $34.7M (up $5.2M YoY); G&A expenses $6.9M (down $0.4M YoY).
- ASPEN-06 Phase 2: Evo-TRP achieved 40.3% ORR vs 26.6% control; mDOR 15.7 vs 7.6 months in ITT.
- Phase 3 registrational trial in gastric/GEJ cancer expected to initiate mid-2025.

## SEC filing metadata
- accession: 0000950170-24-093930
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/0000950170-24-093930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024093930/alxo-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093930
- JSON: https://secwatch.observer/filing/0000950170-24-093930.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.